Reneo Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
OKUR$3.39+6.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm (Ernst & Young LLP; San Diego, California; PCAOB ID: 42) | 97 |
|---|---|
| Consolidated Balance Sheets | 98 |
| Consolidated Statements of Operations and Comprehensive Loss | 99 |
| Consolidated Statements of Changes in Stockholders’ Equity | 100 |
| Consolidated Statements of Cash Flows | 101 |
| Notes to Consolidated Financial Statements | 102 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.